1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Vivimed Labs Ltd.

Vivimed Labs Ltd.

VIVIMEDLAB.NS
Vivimed Labs Ltd.IN flagNational Stock Exchange of India
5.70
INR
-0.09
- -
472.61MMarket Cap
Vivimed Labs Ltd.
VIVIMEDLAB.NS
(National Stock Exchange of India)

Recent

price

5.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
68.94
81.86
95.93
138.07
166.73
170.27
830.32
151.19
143.13
153.28
119.1
103.87
28.53
22.57
17.98
14.02
10.07
Revenue per Share
6.22
9.61
9.06
10.41
8.19
8.89
51.64
26.41
9.44
6.95
-13.16
-9.38
-8.16
-39.62
-5.48
-3.85
-4.21
Basic EPS, GAAP
6.76
0.9
-45.39
-12.57
-34.17
1.99
58.89
7.15
2.6
51.15
9.6
68.4
3.32
4.26
-2.89
-0.21
- -
Free Cash Flow per Basic Share
0.3
0.4
0.34
0.94
1.98
- -
7.2
0.49
0.48
38.45
0.16
- -
- -
- -
- -
- -
- -
Dividend per Share
2.99
2
30.3
34.05
41.27
48.72
292.12
67.83
75.64
42.65
29.02
19.64
2
-27.66
-33.07
-36.87
- -
Book Value per Share
10.21
22.07
41.58
46.02
48.91
46.67
225.01
62.66
114.88
77.66
58.82
33.52
24.96
-14.26
-19.36
-22.73
- -
Tangible Book Value per Share
50
51
70
80
81
81
16
81
83
83
83
83
83
83
83
83
83
Basic Weighted Avg Shares
3,435
4,160
6,683
11,088
13,508
13,795
13,454
12,249
11,812
12,649
9,875
8,615
2,366
1,871
1,491
1,163
836
Sales/Revenue/Turnover
17.72
-81.4
15.84
12.52
10.89
11.02
13.49
30
13.21
10.05
-4.47
-2.54
-11.04
-109.94
-13.85
-24.94
-36.36
Operating Margin (%)
87
102
268
588
661
662
614
583
564
668
669
555
183
1,084
199
202
200
Depreciation Expense
310
488
631
836
664
720
837
2,140
779
574
-1,091
-778
-676
-3,285
-454
-320
-349
Net Income, GAAP
21.78
11.64
18.86
14.6
23.56
7.08
16.27
25.31
11.22
13.14
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
9.03
11.74
9.45
7.54
4.92
5.22
6.22
17.47
6.6
4.54
-11.05
-9.03
-28.6
-175.59
-30.49
-27.49
-41.8
Profit Margin (%)
1,347
722
1,834
2,044
2,265
1,911
2,238
2,770
4,917
3,417
2,190
1,876
1,339
-851
-677
-806
- -
Working Capital
2,353
1,319
3,114
2,969
4,197
4,834
3,261
4,533
3,252
4,248
4,708
578
610
642
645
636
- -
LT Debt
1,449
1,967
4,748
5,091
5,604
5,592
5,278
7,342
12,387
9,438
8,346
4,316
3,643
394
-55
-352
- -
Total Equity
12.16
-84.44
12.75
11.15
9.13
9.65
9.85
16.46
6.94
5.39
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
16.93
34.85
16.76
13.01
10.57
10.92
10.24
16.97
8.32
7.73
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
232.67
389.31
57.07
34.5
21.85
19.77
19.28
41.84
13.28
11.75
-36.82
-38.56
-75.4
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
ST Debt
- -
3,207
- -
LT Borrowings
- -
634
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
83
- -
Market Capitalization
411
411
1,466

Working Capital

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
Total Current Assets
- -
3,406
- -
Cash, Cash Equivalents & STI
- -
490
- -
Accounts Receivable, Net
- -
893
- -
Inventories
- -
527
- -
Total Current Liabilities
- -
4,346
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
3,207
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
34.39%
55.42%
544%
Free Cash Flow
246.59%
57.09%
-92.7%
Net Income, GAAP
1.97%
45.61%
-29.67%
Sales/Revenue/Turnover
-17.84%
-29.71%
-22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
354
336
415
386
1,491
2025
294
248
365
256
1,163
2026
214
206
160
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.88
-2.45
-1.94
- -
-5.48
2025
-1.84
-0.62
-0.72
- -
-3.85
2026
-0.66
-0.88
-2
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
OWC Pharmaceutical Research Corp. (OWCP)
Almirall, S.A. (LBTSF)
Boiron S.A. (0DTF.L)
FUREN Group Pharmaceutical Co., Ltd. (600781.SS)
Flower One Holdings Inc. (FLOOF)
Ionic Brands Corp. (IONC.CN)
Business
Vivimed Labs Ltd, headquartered in Hyderabad, India and founded in 1988, manufactures and supplies specialty chemicals and pharmaceutical products to global markets in over 50 countries. The company produces active pharmaceutical ingredients including generic APIs and intermediates via its subsidiary Uquifa with facilities in Spain and Mexico; finished dosage formulations such as tablets, capsules, syrups, ointments and nasal sprays for areas including diabetes, tuberculosis, oncology, nutritional supplements, hygiene and infectious diseases; and specialty chemicals encompassing active ingredients for home and personal care like triclosan preservatives, sunscreens, anti-wrinkle agents, skin lighteners, anti-dandruff compounds, hair growth promoters, hair conditioners, anti-microbials and oral care products, alongside hair dyes under the Jarocol brand, photochromic dyes under Reversacol, imaging chemicals, nutraceuticals, natural actives, colors and dyes. It operates manufacturing plants in India including sites in Hyderabad, Haridwar, Kashipur and Bidar, R&D labs in India and the UK, and strategic business units Vivimed Labs USA Inc and Vivimed Labs Europe with a marketing office in China; the company provides contract development and manufacturing organization services in APIs and formulations targeting pharmaceutical firms, personal care brands and industrial clients primarily in the US, Europe, erstwhile USSR countries, Africa and Asia. Recent developments include the 2023 acquisition of a US FDA-approved solid oral dosage facility in Alathur, Tamil Nadu from Actavis Pharma Manufacturing for Rs 122 crore along with two Abbreviated New Drug Applications to bolster generics revenue; in October 2025, its debt obligations were assigned from State Bank of India to Rare Asset Reconstruction Ltd encompassing all security interests to support financial restructuring; and ongoing quarterly financial reporting shows net sales of Rs 25.61 crore for Q4 FY2025 with persistent losses amid sales declines, reflecting efforts to stabilize operations through asset optimization and compliance-focused expansions.